Rivaroxaban OK for stroke prevention in cancer patients

July 13, 2017

(HealthDay)—The safety and efficacy of rivaroxaban treatment for nonvalvular atrial fibrillation (AF) in patients with active cancer is similar to the general population, according to a study published in the July 15 issue of the American Journal of Cardiology.

Eva S. Laube, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues assessed the safety and efficacy of rivaroxaban in 163 patients with active cancer and AF treated from Jan. 1, 2014, to March 31, 2016. Outcomes were assessed from medical records.

After adjusting for competing risks, the researchers found that the estimated one-year cumulative incidence of was 1.4 percent and major bleeding was 1.2 percent. At one year, the risk of clinically relevant nonmajor bleeding leading to discontinuation of anticoagulation was 14.0 percent, while the cumulative incidence of mortality was 22.6 percent, reflecting an active cancer population. There was one death following an acute ischemic cerebrovascular insult.

"The safety and efficacy of rivaroxaban treatment for nonvalvular AF in patients with active is comparable to the results of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study in the ," the authors write.

Explore further: Lower risk of gastrointestinal bleeding for apixaban

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

DAPT use variable in patients with A-fib at risk of stroke

August 16, 2016
(HealthDay)—For patients with atrial fibrillation at moderate to high risk of stroke, dual antiplatelet therapy (DAPT) use is variable among those undergoing percutaneous coronary intervention (PCI), according to a study ...

More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

October 22, 2012
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

Low bleeding and stroke rates in AF patients given rivaroxaban for stroke prevention

September 1, 2015
Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today. The findings confirm clinical ...

Well-managed warfarin therapy associated with low risk of complications in patients with atrial fibrillation

April 20, 2016
In a study published online by JAMA Cardiology, Fredrik Björck, M.D., of Umea University, Umea, Sweden and colleagues evaluated the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular atrial ...

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

January 17, 2017
(HealthDay)—For patients with newly diagnosed atrial fibrillation (AF), inpatient costs are lower with dabigatran and rivaroxaban than with warfarin, according to a letter published online in the Jan. 24 issue of the Journal ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.